{"id":"abagovomab","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00103545","NCT00058435","NCT00418574"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2004","type":"neutral","milestone":"Phase 1 Initiated","description":"Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or — Fallopian Tube Cancer"},{"date":"2010","type":"negative","milestone":"Phase 3 Initiated","description":"Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Pati — Ovarian Cancer. Trial terminated early."}],"aiSummary":"Abagovomab is a monoclonal antibody vaccine designed for immunotherapy in ovarian cancer. It stimulates the immune system to target tumor cells. Its key differentiator is its use in active immunotherapy to prolong remission in ovarian cancer patients.","brandName":"ABAGOVOMAB","companyId":"unknown","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Monoclonal antibody","drugClass":"","explanation":"Abagovomab is a type of cancer treatment that works by helping the body's immune system recognize and attack cancer cells. It is given as a vaccine, which means it trains the immune system to identify specific markers on cancer cells so it can destroy them more effectively. This approach is different from traditional chemotherapy because it aims to boost the body's natural defenses rather than directly killing cancer cells with drugs.","oneSentence":"Abagovomab is a vaccine that helps the immune system fight ovarian cancer by targeting tumor cells.","technicalDetail":"Abagovomab is a monoclonal antibody vaccine that targets CA-125, a tumor-associated antigen commonly found in ovarian cancer cells. By mimicking CA-125, it stimulates both humoral and cellular immune responses against tumors expressing this antigen. The vaccine activates T-cells and B-cells to recognize and attack CA-125 positive cancer cells."},"commercial":null,"references":[],"biosimilars":[],"companyName":"","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"ABAGOVOMAB","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00103545","phase":"Phase 1","title":"A Phase I/II Trial of ACA 125 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer","status":"COMPLETED","sponsor":"AGO Study Group","isPivotal":false,"enrollment":36,"indication":"Ovarian Cancer, Fallopian Tube Neoplasms","completionDate":"2004-08"},{"nctId":"NCT00058435","phase":"Phase 1","title":"Phase I Trial of the Monoclonal Anti-Idiotype Antibody ACA125 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":0,"indication":"Fallopian Tube Cancer, Ovarian Cancer","completionDate":"2004-03"},{"nctId":"NCT00418574","phase":"Phase 2","title":"A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy","status":"TERMINATED","sponsor":"Menarini Group","isPivotal":true,"enrollment":888,"indication":"Ovarian Cancer","completionDate":"2011-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Monoclonal antibody","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}